Becton Dickinson & Co. 2024-02-14 Health serious FDA
Health · FDA · Recall #FDA-Z-1038-2024
BD BBL Sensi Disc Rifampin- 5 ug, used for semi-quantitative in vitro susceptibility… Recall
Issued February 14, 2024 · Becton Dickinson & Co.
In February 2024, Becton Dickinson & Co. recalled the BD BBL Sensi Disc Rifampin- 5 ug, used for semi-quantitative in vitro susceptibility…, a serious health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.
What you should do
- 1 Stop using BD BBL Sensi Disc Rifampin- 5 ug, used for semi-quantitative in vitro susceptibility… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Becton Dickinson & Co. to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Becton Dickinson & Co.
- Category
- Health
- Recall date
- February 14, 2024
- Units affected
- Not reported
- Sold at
- Domestic distribution nationwide. International distribution worldwide.
- Recall number
- FDA-Z-1038-2024
- Made in
- United States
- Issuing agency
- FDA
In context
- Becton Dickinson & Co. has 7 recalls in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 737th Health recall we've logged in 2024.